Dr. Brad McGregor

And as EVP came out, it looked so good.

They said, well, why don't we add EV, right?

And so the design of the trial was looking at just the EV arm.

So it's EV PEMBRO conditions standard dosing for nine weeks, so three cycles.

followed by surgery, followed by six additional cycles of ED Pembro.

And then there's a total of 17 cycles of Pembro in all, right?

So for a total of a year versus going right to surgery.

And so that was the design.

I think as they went through, they allow patients to assist

cis-refusing, that was a minority of patients.

Starting out with, if you look at who is enrolled in trial, we haven't seen the paper yet, but these were sick patients, right?

Meeting age was in their mid-70s.

A majority of these patients had T3 diabetes.

disease, nearly all but 20 or 30% had poor renal function.

I mean, these were the patients we see in the clinic, right?

These are the patients that come in.

And what we saw is that there was an improvement

This leads to a significant improvement in both EFS and overall survival with addition of perioperative ED PEMRO versus surgery alone with a path CR rate, and depending on what you use as denominator patients who went to surgery or whatever, but it was well over 50%, which is unheard of.

We haven't seen that with even dose-dense and back.

in some of these trials.